Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12568300rdf:typepubmed:Citationlld:pubmed
pubmed-article:12568300lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0005953lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0018951lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C2004454lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0243065lld:lifeskim
pubmed-article:12568300lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:12568300pubmed:issue1lld:pubmed
pubmed-article:12568300pubmed:dateCreated2003-2-5lld:pubmed
pubmed-article:12568300pubmed:abstractTextWe describe an interesting case of a patient with chronic myelogenous leukemia (CML) who developed sustained severe bone marrow aplasia after 2 years and 11 months of interferon-alpha (IFN-alpha) therapy but demonstrated recovery of normal hematopoiesis when treated with immunosuppressive therapy with granulocyte-colony stimulating factor (G-CSF). Administration of G-CSF resulted in a partial recovery of hematopoiesis, and after starting immunosuppressive therapy, the patient was no longer dependent on blood transfusions. Moreover, her bone marrow had no Philadelphia chromosome-positive clones. According to the results of the present case, bone marrow recovery can be achieved with immunosuppressive therapy and a fatal outcome avoided, even in CML patients suffering from sustained bone marrow aplasia during IFN-alpha treatment.lld:pubmed
pubmed-article:12568300pubmed:languageenglld:pubmed
pubmed-article:12568300pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12568300pubmed:citationSubsetIMlld:pubmed
pubmed-article:12568300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12568300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12568300pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12568300pubmed:statusMEDLINElld:pubmed
pubmed-article:12568300pubmed:monthJanlld:pubmed
pubmed-article:12568300pubmed:issn0925-5710lld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:SaitoHidehiko...lld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:TanimotoMitsu...lld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:YamamotoKazuh...lld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:KatoChiakiClld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:EmiNobuhikoNlld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:YokozawaToshi...lld:pubmed
pubmed-article:12568300pubmed:authorpubmed-author:HishidaAsahiAlld:pubmed
pubmed-article:12568300pubmed:issnTypePrintlld:pubmed
pubmed-article:12568300pubmed:volume77lld:pubmed
pubmed-article:12568300pubmed:ownerNLMlld:pubmed
pubmed-article:12568300pubmed:authorsCompleteYlld:pubmed
pubmed-article:12568300pubmed:pagination55-9lld:pubmed
pubmed-article:12568300pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:meshHeadingpubmed-meshheading:12568300...lld:pubmed
pubmed-article:12568300pubmed:year2003lld:pubmed
pubmed-article:12568300pubmed:articleTitleRecovery of normal hematopoiesis after severe bone marrow aplasia induced by interferon-alpha in a patient with chronic myelogenous leukemia.lld:pubmed
pubmed-article:12568300pubmed:affiliationFirst Department of Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.lld:pubmed
pubmed-article:12568300pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12568300pubmed:publicationTypeReviewlld:pubmed
pubmed-article:12568300pubmed:publicationTypeCase Reportslld:pubmed